IMIQUIMOD /g
PreclinicalSmall molecule
IMIQUIMOD /g is one of 30 small molecule programs targeting Cutaneous Lupus Erythematosus. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
29
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
32 competitors in Cutaneous Lupus Erythematosus
#DrugCompanyPhaseTrials
1Xeljanz
PPrism Pharmaceuticals
Approved
BMS-986165
Bristol-Myers SquibbApproved
Trexall
Alnylam PharmaceuticalsPhase 3
Plaquenil
Alnylam PharmaceuticalsPhase 3
Saphnelo
AstraZenecaPhase 3
Revlimid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Jyseleca
GileadPhase 2
Litifilimab
BiogenPhase 3
Sotyktu
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 2
Prograf
VVeloxis Pharmaceuticals
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for IMIQUIMOD /g. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details